Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.
Paul S
PS
Yamauchi
Nicholas J
NJ
Lowe
Vivian
V
Gindi
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D015897:Comorbidity; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000453:epidemiology*; D011241:Prednisone / Q000008:administration & dosage; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D011241:Prednisone